The initial discovery of such activators would likely begin with the development of a biochemical assay designed to measure the GTPase activity of mGBP8. This assay could be based on the protein's ability to hydrolyze GTP to GDP, a reaction that can be monitored using various techniques, such as the release of inorganic phosphate or the use of fluorescently labeled GTP analogs. The high-throughput screening (HTS) of chemical libraries using these assays would aim to identify compounds that increase the GTP hydrolysis rate, signifying enhanced mGBP8 activity. Hits from the HTS would be considered candidate mGBP8 activators and would be subjected to further validation to confirm their specific activity.
Once candidate activators are identified, secondary validation involves a more detailed examination of the interaction between these molecules and mGBP8. Techniques such as isothermal titration calorimetry (ITC) would provide data on the thermodynamics of the binding interaction, while surface plasmon resonance (SPR) would offer insight into the kinetics of the activator binding to mGBP8. These methods would help confirm whether the observed increase in activity is due to a direct effect of the activator on mGBP8. Further studies, including X-ray crystallography or cryo-electron microscopy (cryo-EM), could provide a detailed three-dimensional structure of the mGBP8 in complex with the activator, shedding light on the molecular basis for activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase leading to increased cAMP levels, which may enhance mGBP8's GTPase activity through cAMP-dependent protein kinase (PKA) signaling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
This polyphenol inhibits protein kinases, potentially reducing inhibitory phosphorylation events and thereby enhancing mGBP8's GTPase activity involved in immune response mechanisms. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates protein kinase C (PKC), which may enhance mGBP8's antiviral mechanisms by modulating downstream regulatory proteins involved in the innate immune system. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor which might upregulate pathways leading to the activation of mGBP8, potentially enhancing its role in the immune response to intracellular pathogens. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Binds to sphingosine-1-phosphate receptors potentially influencing the actin cytoskeleton and enhancing mGBP8's localization to pathogen-containing vacuoles for immune response. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A calcium ionophore that increases intracellular calcium, which may enhance mGBP8's role in calcium-dependent signaling pathways related to its immune effector functions. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A broad-spectrum protein kinase inhibitor that may enhance mGBP8's activity by selectively modulating kinases involved in its regulation during the immune response. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor that can facilitate changes in the actin cytoskeleton, potentially enhancing mGBP8's ability to target pathogens through cytoskeletal dynamics. | ||||||